Cite
HARVARD Citation
Tsuji, A. et al. (n.d.). P-243Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. Annals of oncology. p. . [Online].